Thomas Hope, MD, director of molecular therapy for MI&T, will lead the introduction and use of molecular imaging-guided therapies. As part of this role, he will serve as chair the Cancer Center's new Molecular Imaging and Radionuclide Therapy Site Committee.

After receiving his undergraduate and medical degrees from Duke University and Stanford University, respectively, Dr. Hope completed his residency at UCSF and clinical fellowship in Body MRI and Nuclear Medicine at Stanford.


An international leader in PET/MR research and the translation of new molecular imaging agents, Dr. Hope launched the highly successful PSMA prostate program at UCSF and championed the use of multiple new targeted therapies to treat patients with neuroendocrine and other tumors. He currently serves as principal investigator on grants from the NIH, the Prostate Cancer Foundation. He is the recipient of numerous accolades in molecular imaging, including the Henkin Fellow and Marc Tetalman Memorial Award from the Society of Nuclear Medicine and Molecular Imaging, the Young Investigator Award from the Prostate Cancer Foundation and the Wylie J. Dodds Research Award from the Society of Abdominal Radiology.

Dr. Hope has achieved distinction through his international academic footprint championing molecular imaging and his vast experience in new agent program development.

Miguel Hernandez Pampaloni, MD, director of nuclear cardiology for MI&T, will oversee nuclear cardiology and develop new techniques to evaluate cardiac metabolism and function. Along with Dr. Hope, he will also serve as vice-chair of the Cancer Center's new Molecular Imaging and Radionuclide Therapy Site Committee. He received his MD and PhD from the Universidad Complutense School of Medicine in Madrid and completed residencies in Nuclear Medicine at both San Carlos Hospital in Madrid and at the University of Pennsylvania.

He also served as a postdoctoral fellow in Cardiovascular Nuclear Medicine in the UCLA Department of Medical and Molecular Pharmacology and at Hammersmith Hospital, Imperial College London, UK.

Dr. Pampaloni is published broadly and has spoken to national and international audiences on multiple topics in nuclear medicine and molecular imaging, especially quantitative myocardial blood flow and ischemic cardiomyopathy. He led the Nuclear Medicine section for a decade, during which time he directed the opening of operations at Mission Bay Hospital, helped to bring multiple new imaging and treatment agents to clinical practice, and guided the professional development of numerous highly successful residents, fellows and faculty. He has served as PI and co-investigator on multiple clinical trials and received numerous accolades for his scientific presentations.

Molecular Imaging Homepage